Skip to main content
OpenTrials

Clinical trial condition

Histiocytic Disorders, Malignant

Explore clinical trials studying Histiocytic Disorders, Malignant. Study availability and eligibility vary by location and protocol.

260 public trials 43 recruiting studies
Refine in advanced search Browse all conditions

Histiocytic Disorders, Malignant trial results

Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT07121946

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Follicular Lymphoma ( FL), +18 more
Locations
  • City of Hope Duarte, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center - Bergen New York, United States
View Trial Details
Recruiting

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

NCT07007052

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Disease Attributes, +16 more
Locations
  • AMIENS - CH Amiens Picardie Site Sud Amiens, France
  • ANGERS - CHU - Maladies du sang Angers, France
  • ARGENTEUIL - Centre hospitalier Victor Dupouy Argenteuil, France
  • AVIGNON - Centre Hospitalier Avignon, France
View all 34 locations
View Trial Details
Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT03113643

Conditions
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, +16 more
Locations
  • City of Hope Duarte, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations
  • LLC ARENSIA Exploratory Medicine Tbilisi, Georgia
  • IMSP Institute of Oncology, ARENSIA Exploratory Medicine Chisinau, Moldova
  • Hospital Beata Maria Ana Madrid, Spain
  • Hospital Fundación Jiménez Diaz Madrid, Spain
View Trial Details
Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

NCT05430971

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Hematologic Diseases, +11 more
Locations
  • Sylvester Comprehensive Cancer Center, University of Miami Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Seattle Children's Cancer and Blood Disorders Center Seattle, Washington, United States
  • Hematology Center named after prof. R. Yeolyan Yerevan, Armenia
View all 22 locations
View Trial Details
Recruiting

CAR-T Followed by Bispecific Antibodies

NCT04889716

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +6 more
Locations
  • University of Nebraska Medical Center Omaha, Nebraska, United States
  • Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions